Evanston-based biopharmaceutical company Aptinyx Inc. Thursday said a drug it is studying to treat patients with painful diabetic peripheral neuropathy failed a recent clinical study.The drug, NYX-2925, did not achieve statistically significant separation from a placebo on the study’s primary endpoint, which assessed the change from baseline in average daily pain on the numeric rating scale, the company said.
Related posts
-
Bottlenose dolphin born at Brookfield Zoo Chicago, and baby is ‘very strong’
Brookfield Zoo Chicago is celebrating its first bottlenose dolphin birth in more than a decade. -
Hoffman Estates police: Man charged with attempted murder of 87-year-old acquaintance
A man has been been accused of attempted murder of an 87-year-old man, Hoffman Estates police... -
Girls soccer: Barrington strikes first, can’t hold on in state semifinal loss to O’Fallon
Barrington's dream of playing for the state soccer title were dashed after downstate power O'Fallon claimed...